Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Lung Cancer AJCC v8: early-phase trial registry
17 of 41 indexed Stage III Lung Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #357 of 28,707 conditions by registered trial count.
41 US clinical trials · 17 currently recruiting · #357 of 28,707 conditions by registered trial count
Stage III Lung Cancer AJCC v8: 41 US clinical trials tracked, 17 recruiting.
Stage III Lung Cancer AJCC v8 is the subject of 41 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 11 of these trials.
Enrollment posture brief
Registry condition stage-iii-lung-cancer-ajcc-v8
OPEN 17 | RECR 41% | LATE 3 | EARLY 27 | RANK #357 | SPON 11
Volume-matched condition peers
Nearest open-share peer: Glaucoma (41% recruiting · 94 trials)
Stage III Lung Cancer AJCC v8 lists 17 open slots (41% of 41 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Lung Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Lung Cancer AJCC v8 recruits in line with its size-band peers.
17 of 41 indexed trials (41.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Lung Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 11 of 41 trials (26.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Lung Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 47 among the 41 trials that report a genuine target (sentinel values excluded). 32 of those (78%) plan for fewer than 100 participants.
-
Stage III Lung Cancer AJCC v8 research is mostly interventional.
40 interventional and 1 observational studies make up this index (97.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
41 total, page 1 of 1
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Mayo Clinic
NCT06075524
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
NCT05624996
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
City of Hope Medical Center
NCT06139627
Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation
M.D. Anderson Cancer Center
NCT05010109
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
Thomas Jefferson University
NCT05502523
A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer
Mayo Clinic
NCT06122064
New York Better Breathing Study
Roswell Park Cancer Institute
NCT06869447
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
NCT04892953
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Emory University
NCT06495125
Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
M.D. Anderson Cancer Center
NCT04789681
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05198830
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
National Cancer Institute (NCI)
NCT07012031
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
Rutgers, The State University of New Jersey
NCT04751747
GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
NCT07017829
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT05136846
Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
NCT06731270
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
City of Hope Medical Center
NCT06249282
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04092283
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
National Cancer Institute (NCI)
NCT03811002
Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
NCT04946279
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05096663
Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment
M.D. Anderson Cancer Center
NCT03731585
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02595931
Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
NCT03830918
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Roswell Park Cancer Institute
NCT02955290
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT04073745
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
NCT04701307
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
NCT04310020
A Nurse-Led Intervention for Fear of Progression in Advanced Cancer
City of Hope Medical Center
NCT04819997
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
NCT02983578
Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
NCT03225664
NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04505267
Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT05017025
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
NCT04514497
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03637816
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
M.D. Anderson Cancer Center
NCT04013542
Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer
City of Hope Medical Center
NCT05166616
Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors
University of California, Irvine
NCT05334329
Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC
City of Hope Medical Center
NCT04227028
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
University of Southern California
NCT05340309
Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer
City of Hope Medical Center
NCT03776253
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 12 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Lung Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Lung Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Lung Cancer AJCC v8 page
41 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 Stage III Lung Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage III Lung Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Lung Cancer AJCC v8 condition card totals 41 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.